methyl 4-[(4-methoxyphenyl)amino]-6-(methylcarbamoyl)quinoline-3-carboxylate | 1153631-95-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: methyl 4-[(4-methoxyphenyl)amino]-6-(methylcarbamoyl)quinoline-3-carboxylate
• 英文别名: methyl 4-(4-methoxyanilino)-6-(methylcarbamoyl)quinoline-3-carboxylate
• CAS: 1153631-95-8
• 化学式: C₂₀H₁₉N₃O₄
• 分子量: 365.389
• InChiKey: WFGNDQDAAXBZBY-UHFFFAOYSA-N

物化性质

• 沸点：
  580.8±50.0 °C(predicted)
• 密度：
  1.281±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  89.6
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  甲醇 、 4-[(4-methoxyphenyl)amino]-6-(methyl-carbamoyl)quinoline-3-carboxylic acid 在 4-二甲氨基吡啶 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以60%的产率得到methyl 4-[(4-methoxyphenyl)amino]-6-(methylcarbamoyl)quinoline-3-carboxylate
  参考文献：
  名称：

  [EN] QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS
  [FR] COMPOSÉS ET PROCÉDÉS

  摘要：

  公开号：

  WO2009063070A3

文献信息

• QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS
  申请人：Westman Jacob

  公开号：US20110053976A1

  公开（公告）日：2011-03-03

  A compound of formula (I) as well as pharmaceutically acceptable salts thereof. A pharmaceutical composition having a therapeutically effective amount of the compound. The compound is useful for the treatment of cancer, diabetic retinopathy, age-related macular degeneration, inflammation, stroke, ischemic myocardium, atherosclerosis, macular edema or psoriasis.

  化合物式（I）及其药学上可接受的盐。含有治疗有效量该化合物的药物组合物。该化合物可用于治疗癌症、糖尿病性视网膜病变、年龄相关性黄斑变性、炎症、中风、缺血性心肌、动脉粥样硬化、黄斑水肿或银屑病。
• Quinoline derivatives and their use as tyrosine kinase inhibitors
  申请人：Westman Jacob

  公开号：US08557843B2

  公开（公告）日：2013-10-15

  A compound of formula (I) as well as pharmaceutically acceptable salts thereof. A pharmaceutical composition having a therapeutically effective amount of the compound. The compound is useful for the treatment of cancer, diabetic retinopathy, age-related macular degeneration, inflammation, stroke, ischemic myocardium, atherosclerosis, macular edema or psoriasis.

  化合物公式（I）及其药学上可接受的盐。含有治疗有效量该化合物的药物组合物。该化合物可用于治疗癌症、糖尿病性视网膜病变、老年性黄斑变性、炎症、中风、缺血性心肌、动脉硬化、黄斑水肿或银屑病。
• COMPOUNDS AND METHODS
  申请人：ClanoTech AB

  公开号：EP2220047A2

  公开（公告）日：2010-08-25
• Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases
  申请人：Clanotech AB

  公开号：US20150031723A1

  公开（公告）日：2015-01-29

  A new medical therapy, and more particularly certain quinoline compounds which are anti-angiogenic integrin aplha5beta1 inhibitors, for use in the treatment of fibrosis, or a fibrosis-related disease, such as a fibrotic disease affecting the lung, liver, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, stomach, large intestine, small intestine, colon, uterus, nervous system, testis, adrenal gland, artery, vein, biliary tract, or eye.
• US8557843B2
  申请人：——

  公开号：US8557843B2

  公开（公告）日：2013-10-15